Pharmacokinetics, Safety, and Tolerability of Fevipiprant (QAW039), a Novel CRTh2 Receptor Antagonist: Results From 2 Randomized, Phase 1, Placebo‐Controlled Studies in Healthy Volunteers

We evaluated the pharmacokinetics (PK), safety, and tolerability of a novel oral CRTh2 antagonist, fevipiprant (QAW039), in healthy subjects. Peak concentrations of fevipiprant in plasma were observed 1‒3 hours postdosing. Concentrations declined in a multiexponential manner, followed by an apparent...

Descripción completa

Detalles Bibliográficos
Autores principales: Erpenbeck, Veit J., Vets, Eva, Gheyle, Lien, Osuntokun, Wande, Larbig, Michael, Neelakantham, Srikanth, Sandham, David, Dubois, Gerald, Elbast, Walid, Goldsmith, Paul, Weiss, Markus
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2016
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5071756/
https://www.ncbi.nlm.nih.gov/pubmed/27310331
http://dx.doi.org/10.1002/cpdd.244

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5071756/
https://www.ncbi.nlm.nih.gov/pubmed/27310331
http://dx.doi.org/10.1002/cpdd.244

Ejemplares similares